Cadila Healthcare hits 52 week high with mind blowing Q2 results

Cadila Healthcare (CHL) reported Q2FY16 results. The company's consolidated revenue increased by 16.66 per cent to Rs 2459 crore in Q2FY16 as compared to same period in previous financial year. Its total expenditure increased by 8.96 per cent amounting to Rs 1838 crore in Q2FY16 on yearly basis. CHL's total expenditure increased largely because of a 20.76 per cent increment in other expense,6.86 per cent increment in raw material prices, and 16.27 per cent increment in employee cost during the quarter.

The EBITDA of CHL boosted by 47.53 per cent to Rs 621 crore in Q2FY16 as compared to the same period in previous fiscal year. The company's EBITDA margin expanded by 528 basis points to 25.25 per cent in Q2FY16 on yearly basis. Its net profit also rose by 40.5 per cent to Rs 391 crore in Q2FY16 as compared to same period in previous financial year. CHL's net profit margin expanded by 270 basis points to 15.89 per cent during Q2FY16 on yearly basis.

CHL's US sales stood at Rs 1004 crore in registering growth of 25 per cent during the quarter on yearly basis. The company received approval for 1 new product from US FDA and 2 products were launched in US market. In domestic formulations market, the company launched 13 new products, including line extensions, of which 4 products were the first to be launched in India. In Mexico, the company launched 2 new products during the quarter.

CHL's shareholding pattern indicates that FII holdings contracted by 30 basis points to 6.73 per cent and DII holdings expanded by 34 basis points to 8.35 per cent in September 2015 quarter. The share price of the company increased by 5.27 per cent on BSE in early trades and is trading at Rs 442.35 on intraday basis. The share price of CHL hit a records high on bourses.

CHL is primarily engaged in the business of manufacturing and marketing of pharmaceutical products, both active pharmaceutical ingredients and finished dosage formulations. The Company is also involved in basic new drug discovery research, several other newer technology products, such as transdermals and biosimilars and generic product development activities. Its product portfolio includes active pharmaceutical ingredient (API), veterinary and human formulations. CHL has a presence in India and other generic markets across the world. The Company has operations in approximately 15 countries around the world.